Literature DB >> 22169260

A three-step protocol for lead optimization: quick identification of key conformational features and functional groups in the SAR studies of non-ATP competitive MK2 (MAPKAPK2) inhibitors.

Xianhai Huang1, Xiaohong Zhu, Xiao Chen, Wei Zhou, Dong Xiao, Sylvia Degrado, Robert Aslanian, James Fossetta, Daniel Lundell, Fang Tian, Prashant Trivedi, Anandan Palani.   

Abstract

A three-step protocol for SAR development was introduced and applied to the SAR studies of the MK2 inhibitor program. Following this protocol, key conformational features and functional groups for improving MK2 inhibitor activity were quickly identified. Through this effort, the initial gap observed between in vitro binding activity and cellular activity in the lead identification stage was very much reduced. Compound 28 was identified with single digit binding activity (IC(50)=8 nM) and good cellular activity (EC(50)=310 nM). This provides further evidence that non-ATP-competitive binding MK2 inhibitors are feasible by targeting the outside ATP pocket.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22169260     DOI: 10.1016/j.bmcl.2011.11.074

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  8 in total

1.  Activation of calcium/calmodulin-dependent protein kinase II in obesity mediates suppression of hepatic insulin signaling.

Authors:  Lale Ozcan; Jane Cristina de Souza; Alp Avi Harari; Johannes Backs; Eric N Olson; Ira Tabas
Journal:  Cell Metab       Date:  2013-11-21       Impact factor: 27.287

2.  Treatment of Obese Insulin-Resistant Mice With an Allosteric MAPKAPK2/3 Inhibitor Lowers Blood Glucose and Improves Insulin Sensitivity.

Authors:  Lale Ozcan; Xiaoming Xu; Shi-Xian Deng; Devram S Ghorpade; Tiffany Thomas; Serge Cremers; Brian Hubbard; Michael H Serrano-Wu; Matthias Gaestel; Donald W Landry; Ira Tabas
Journal:  Diabetes       Date:  2015-06-11       Impact factor: 9.461

3.  Synthesis and SAR Studies of Fused Oxadiazines as γ-Secretase Modulators for Treatment of Alzheimer's Disease.

Authors:  Xianhai Huang; Wei Zhou; Xiaoxiang Liu; Hongmei Li; George Sun; Mihirbaran Mandal; Monica Vicarel; Xiaohong Zhu; Chad Bennett; Troy McCraken; Dmitri Pissarnitski; Zhiqiang Zhao; David Cole; Gioconda Gallo; Zhaoning Zhu; Anandan Palani; Robert Aslanian; John Clader; Michael Czarniecki; William Greenlee; Duane Burnett; Mary Cohen-Williams; Lynn Hyde; Lixin Song; Lili Zhang; Inhou Chu; Alexei Buevich
Journal:  ACS Med Chem Lett       Date:  2012-09-04       Impact factor: 4.345

Review 4.  Targeting Mitogen-Activated Protein Kinase-Activated Protein Kinase 2 (MAPKAPK2, MK2): Medicinal Chemistry Efforts To Lead Small Molecule Inhibitors to Clinical Trials.

Authors:  Mario Fiore; Stefano Forli; Fabrizio Manetti
Journal:  J Med Chem       Date:  2015-11-09       Impact factor: 7.446

Review 5.  MAPKAPK2: the master regulator of RNA-binding proteins modulates transcript stability and tumor progression.

Authors:  Sourabh Soni; Prince Anand; Yogendra S Padwad
Journal:  J Exp Clin Cancer Res       Date:  2019-03-08

6.  IL-33 regulates cytokine production and neutrophil recruitment via the p38 MAPK-activated kinases MK2/3.

Authors:  Pierre C McCarthy; Iain R Phair; Corinna Greger; Katerina Pardali; Victoria A McGuire; Andrew R Clark; Matthias Gaestel; J Simon C Arthur
Journal:  Immunol Cell Biol       Date:  2018-10-19       Impact factor: 5.126

7.  Targeting MK2 Is a Novel Approach to Interfere in Multiple Myeloma.

Authors:  Mengjie Guo; Dongdong Sun; Zhimin Fan; Yuxia Yuan; Miaomiao Shao; Jianhao Hou; Yuqi Zhu; Rongfang Wei; Yan Zhu; Jinjun Qian; Fei Li; Ye Yang; Chunyan Gu
Journal:  Front Oncol       Date:  2019-08-08       Impact factor: 6.244

8.  The Role of Mitogen-Activated Protein Kinase-Activated Protein Kinases (MAPKAPKs) in Inflammation.

Authors:  Ugo Moens; Sergiy Kostenko; Baldur Sveinbjørnsson
Journal:  Genes (Basel)       Date:  2013-03-26       Impact factor: 4.096

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.